Novel antiangiogenic therapies for renal cell cancer

Michael S. Gordon, Michael Atkins, Allan Lipton, Walter Stadler, Robert Flanigan, Daniel George, James Yang, Robert Figlin, William Kaelin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Renal cell cancer remains a disease for which highly effective therapy for the majority of patients with metastatic disease is lacking. The biology of clear cell carcinomas and their association with mutations of the von Hippel-Lindau gene and its resultant increased expression of vascular endothelial growth factor (VEGF) make angiogenesis a potentially pathophysiologic mechanism for tumor development. As a result, the use of antiangiogenic therapy is an intriguing concept for the treatment of renal cell cancer. Various agents, aside from the inhibitors of VEGF, have been studied, including thalidomide, low-dose interferon, and novel antiangiogenic agents such as the thrombospondin-1 mimetics. Use of these agents has been associated with some degree of objective response or prolonged stabilization of disease, and their true value needs to be assessed in ongoing prospective studies. Combinations of antiangiogenic agents either with other similarly acting drugs or as a component of a "cocktail" with other noncytotoxic therapies should be explored in this patient population.

Original languageEnglish (US)
Pages (from-to)6377s-6381s
JournalClinical Cancer Research
Volume10
Issue number18 II
DOIs
StatePublished - Sep 15 2004

Fingerprint

Renal Cell Carcinoma
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Thrombospondin 1
Thalidomide
Therapeutics
Interferons
Cell Biology
Prospective Studies
Carcinoma
Mutation
Pharmaceutical Preparations
Population
Genes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Gordon, M. S., Atkins, M., Lipton, A., Stadler, W., Flanigan, R., George, D., ... Kaelin, W. (2004). Novel antiangiogenic therapies for renal cell cancer. Clinical Cancer Research, 10(18 II), 6377s-6381s. https://doi.org/10.1158/1078-0432.CCR-050007
Gordon, Michael S. ; Atkins, Michael ; Lipton, Allan ; Stadler, Walter ; Flanigan, Robert ; George, Daniel ; Yang, James ; Figlin, Robert ; Kaelin, William. / Novel antiangiogenic therapies for renal cell cancer. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 18 II. pp. 6377s-6381s.
@article{b83c76eb2f904c699d23d058aec98ad8,
title = "Novel antiangiogenic therapies for renal cell cancer",
abstract = "Renal cell cancer remains a disease for which highly effective therapy for the majority of patients with metastatic disease is lacking. The biology of clear cell carcinomas and their association with mutations of the von Hippel-Lindau gene and its resultant increased expression of vascular endothelial growth factor (VEGF) make angiogenesis a potentially pathophysiologic mechanism for tumor development. As a result, the use of antiangiogenic therapy is an intriguing concept for the treatment of renal cell cancer. Various agents, aside from the inhibitors of VEGF, have been studied, including thalidomide, low-dose interferon, and novel antiangiogenic agents such as the thrombospondin-1 mimetics. Use of these agents has been associated with some degree of objective response or prolonged stabilization of disease, and their true value needs to be assessed in ongoing prospective studies. Combinations of antiangiogenic agents either with other similarly acting drugs or as a component of a {"}cocktail{"} with other noncytotoxic therapies should be explored in this patient population.",
author = "Gordon, {Michael S.} and Michael Atkins and Allan Lipton and Walter Stadler and Robert Flanigan and Daniel George and James Yang and Robert Figlin and William Kaelin",
year = "2004",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-050007",
language = "English (US)",
volume = "10",
pages = "6377s--6381s",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18 II",

}

Gordon, MS, Atkins, M, Lipton, A, Stadler, W, Flanigan, R, George, D, Yang, J, Figlin, R & Kaelin, W 2004, 'Novel antiangiogenic therapies for renal cell cancer', Clinical Cancer Research, vol. 10, no. 18 II, pp. 6377s-6381s. https://doi.org/10.1158/1078-0432.CCR-050007

Novel antiangiogenic therapies for renal cell cancer. / Gordon, Michael S.; Atkins, Michael; Lipton, Allan; Stadler, Walter; Flanigan, Robert; George, Daniel; Yang, James; Figlin, Robert; Kaelin, William.

In: Clinical Cancer Research, Vol. 10, No. 18 II, 15.09.2004, p. 6377s-6381s.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel antiangiogenic therapies for renal cell cancer

AU - Gordon, Michael S.

AU - Atkins, Michael

AU - Lipton, Allan

AU - Stadler, Walter

AU - Flanigan, Robert

AU - George, Daniel

AU - Yang, James

AU - Figlin, Robert

AU - Kaelin, William

PY - 2004/9/15

Y1 - 2004/9/15

N2 - Renal cell cancer remains a disease for which highly effective therapy for the majority of patients with metastatic disease is lacking. The biology of clear cell carcinomas and their association with mutations of the von Hippel-Lindau gene and its resultant increased expression of vascular endothelial growth factor (VEGF) make angiogenesis a potentially pathophysiologic mechanism for tumor development. As a result, the use of antiangiogenic therapy is an intriguing concept for the treatment of renal cell cancer. Various agents, aside from the inhibitors of VEGF, have been studied, including thalidomide, low-dose interferon, and novel antiangiogenic agents such as the thrombospondin-1 mimetics. Use of these agents has been associated with some degree of objective response or prolonged stabilization of disease, and their true value needs to be assessed in ongoing prospective studies. Combinations of antiangiogenic agents either with other similarly acting drugs or as a component of a "cocktail" with other noncytotoxic therapies should be explored in this patient population.

AB - Renal cell cancer remains a disease for which highly effective therapy for the majority of patients with metastatic disease is lacking. The biology of clear cell carcinomas and their association with mutations of the von Hippel-Lindau gene and its resultant increased expression of vascular endothelial growth factor (VEGF) make angiogenesis a potentially pathophysiologic mechanism for tumor development. As a result, the use of antiangiogenic therapy is an intriguing concept for the treatment of renal cell cancer. Various agents, aside from the inhibitors of VEGF, have been studied, including thalidomide, low-dose interferon, and novel antiangiogenic agents such as the thrombospondin-1 mimetics. Use of these agents has been associated with some degree of objective response or prolonged stabilization of disease, and their true value needs to be assessed in ongoing prospective studies. Combinations of antiangiogenic agents either with other similarly acting drugs or as a component of a "cocktail" with other noncytotoxic therapies should be explored in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=4644326810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644326810&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-050007

DO - 10.1158/1078-0432.CCR-050007

M3 - Article

C2 - 15448034

AN - SCOPUS:4644326810

VL - 10

SP - 6377s-6381s

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18 II

ER -

Gordon MS, Atkins M, Lipton A, Stadler W, Flanigan R, George D et al. Novel antiangiogenic therapies for renal cell cancer. Clinical Cancer Research. 2004 Sep 15;10(18 II):6377s-6381s. https://doi.org/10.1158/1078-0432.CCR-050007